Free Trial Information
BioCentury | Apr 15, 2013
Company News

LJL board of directors update

...BioSystems Inc. , Sunnyvale, Calif. Business: Enabling technology Appointed: Michael Bigham, president and CEO of Coulter Pharmaceutical Inc....
Read More
BioCentury | Mar 25, 2013
Finance

Done with biotech

Done with biotech Three Arch Partners has made only a handful of biotech investments since its formation in 1993, and it is not looking for any more. The VC said last week it has no...
Read More
BioCentury | Apr 30, 2007
Strategy

Scale was elusive

...top selling protease inhibitor for HIV. Companies with late-stage cancer compounds had also disappeared, including Coulter Pharmaceutical Inc....
Read More
BioCentury | Dec 8, 2003
Regulation

PDUFA: Time stands still

...behind closed doors and are never made public. Bexxar, a radiolabeled MAb originally developed by Coulter Pharmaceutical Inc....
Read More
BioCentury | Mar 3, 2003
Company News

Corixa, Idec, GlaxoSmithKline cancer news

...September 2001. At that time, IDPH filed two suits: the first was against CRXA, CRXA's Coulter Pharmaceutical Inc....
Read More
BioCentury | Dec 23, 2002
Product Development

Deconstructing Bexxar

...Rituxan . But one still could argue that the bet was lost: The original sponsor, Coulter Pharmaceutical Inc....
Read More
BioCentury | Jun 3, 2002
Company News

Deltagen management update

...Cancer, Metabolic, Autoimmune/Inflammation Hired: Geoffrey Yarranton as EVP of R&D, formerly SVP of R&D at Coulter Pharmaceutical Inc....
Read More
BioCentury | Apr 1, 2002
Clinical News

Bexxar tositumomab radiolabeled anti-CD20 monoclonal antibody regulatory update

...the FDA within the next 45 days. CRXA acquired Bexxar through its 2000 acquisition of Coulter Pharmaceutical Inc....
Read More
BioCentury | Mar 18, 2002
Clinical News

Bexxar tositumomab radiolabeled anti-CD20 monoclonal antibody regulatory update

...evidence of safety and clinical benefit. CRXA acquired Bexxar tositumomab through its 2000 acquisition of Coulter Pharmaceutical Inc....
Read More
BioCentury | Sep 17, 2001
Company News

XenoPort management update

...while remaining president Hired: William Harris as SVP of finance and CFO, formerly CFO at Coulter Pharmaceutical Inc. WIR...
Read More
Items per page:
1 - 10 of 100
BioCentury | Apr 15, 2013
Company News

LJL board of directors update

...BioSystems Inc. , Sunnyvale, Calif. Business: Enabling technology Appointed: Michael Bigham, president and CEO of Coulter Pharmaceutical Inc....
Read More
BioCentury | Mar 25, 2013
Finance

Done with biotech

Done with biotech Three Arch Partners has made only a handful of biotech investments since its formation in 1993, and it is not looking for any more. The VC said last week it has no...
Read More
BioCentury | Apr 30, 2007
Strategy

Scale was elusive

...top selling protease inhibitor for HIV. Companies with late-stage cancer compounds had also disappeared, including Coulter Pharmaceutical Inc....
Read More
BioCentury | Dec 8, 2003
Regulation

PDUFA: Time stands still

...behind closed doors and are never made public. Bexxar, a radiolabeled MAb originally developed by Coulter Pharmaceutical Inc....
Read More
BioCentury | Mar 3, 2003
Company News

Corixa, Idec, GlaxoSmithKline cancer news

...September 2001. At that time, IDPH filed two suits: the first was against CRXA, CRXA's Coulter Pharmaceutical Inc....
Read More
BioCentury | Dec 23, 2002
Product Development

Deconstructing Bexxar

...Rituxan . But one still could argue that the bet was lost: The original sponsor, Coulter Pharmaceutical Inc....
Read More
BioCentury | Jun 3, 2002
Company News

Deltagen management update

...Cancer, Metabolic, Autoimmune/Inflammation Hired: Geoffrey Yarranton as EVP of R&D, formerly SVP of R&D at Coulter Pharmaceutical Inc....
Read More
BioCentury | Apr 1, 2002
Clinical News

Bexxar tositumomab radiolabeled anti-CD20 monoclonal antibody regulatory update

...the FDA within the next 45 days. CRXA acquired Bexxar through its 2000 acquisition of Coulter Pharmaceutical Inc....
Read More
BioCentury | Mar 18, 2002
Clinical News

Bexxar tositumomab radiolabeled anti-CD20 monoclonal antibody regulatory update

...evidence of safety and clinical benefit. CRXA acquired Bexxar tositumomab through its 2000 acquisition of Coulter Pharmaceutical Inc....
Read More
BioCentury | Sep 17, 2001
Company News

XenoPort management update

...while remaining president Hired: William Harris as SVP of finance and CFO, formerly CFO at Coulter Pharmaceutical Inc. WIR...
Read More
Items per page:
1 - 10 of 100